8-K 1 a78014e8-k.txt FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 -------------------- FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES AND EXCHANGE ACT OF 1934 December 20, 2001 Date of Report (Date of earliest event reported) -------------------- NEOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 000-28782 93-0979187 (State or other Jurisdiction (Commission File Number) (IRS Employer of Incorporation) Identification Number) 157 TECHNOLOGY DRIVE 92618 IRVINE, CALIFORNIA (Zip Code) (Address of principal executive offices)
(949) 788-6700 (Registrant's telephone number, including area code) N/A (Former Name or Former Address, if Changed Since Last Report) ITEM 5. OTHER EVENTS. On December 20, 2001, NeoTherapeutics, Inc. issued a news release announcing that it's subsidiary, NeoGene Technologies, entered into a second license agreement with Pfizer Inc. for the use of an orphan receptor identified by NeoGene. The text of the press release is set forth in Exhibit 99.1 attached to this report and incorporated herein by this reference. ITEM 7. EXHIBITS Exhibits: 99.1 Press Release dated December 20, 2001. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEOTHERAPEUTICS, INC. Date: December 20, 2001 By: /s/ Samuel Gulko -------------------------- Name: Samuel Gulko Title: Senior Vice President, Finance, Chief Financial Officer, Secretary and Treasurer
Exhibit Number Document Description ------ -------------------- 99.1 Press Release dated December 20, 2001.